Detection of toxoplasmosis in patients with end-stage renal disease by enzyme-linked immunosorbent assay and polymerase chain reaction methods

2012 ◽  
Vol 112 (1) ◽  
pp. 163-168 ◽  
Author(s):  
J. Saki ◽  
S. Khademvatan ◽  
S. Soltani ◽  
H. Shahbazian
Keyword(s):  
Polymerase Chain Reaction ◽  
Renal Disease ◽  
Immunosorbent Assay ◽  
End Stage Renal Disease ◽  
Enzyme Linked Immunosorbent Assay ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Recurrent Positivity of SARS-CoV-2 RNA in a Clinically Recovered COVID-19 Patient with End Stage Renal Disease: A Case Report

2020 ◽  
Vol 58 (231) ◽  
Author(s):  
Richa Nepal ◽  
Kalyan Sapkota ◽  
Santosh Gurung ◽  
Pramod Paudel ◽  
Prateek Neupane ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Clinical Implications ◽  
Rt Pcr ◽  
Chain Reaction ◽  
History Of ◽  
Polymerase Chain ◽  
Stage Renal Disease ◽  
End Stage ◽  
Immunocompetent Patients

Recurrent or persistent positivity of SARS-CoV-2 RNA in clinically recovered COVID-19 patients have been reported worldwide. However, replication competent live viruses were not recovered beyond two to three weeks from onset of symptoms in mild to severe cases of COVID-19. End stage renal disease is characterized by uremia induced immune dysfunction that increases the risk of infectious diseases including COVID-19. The clinical implications of recurrent or persistently positive SARS-CoV-2 RNA in immunocompromised patients are difficult to be generalized to findings as in immunocompetent patients. We report a case of end stage renal disease with recent history of recovered COVID-19 pneumonia, who again presented with positive reverse transcriptase- polymerase chain reaction (RT-PCR) test for SARS-CoV-2 RNA.

scholarly journals Analysis of Endocan Levels in Hypertensive Patients as Risk Factors of Chronic Kidney Disease

2020 ◽  
Vol 27 (1) ◽  
Author(s):  
Suryani Jamal ◽  
Uleng Bahrun ◽  
Ibrahim Abdul Samad ◽  
Fitriani Mangarengi ◽  
Hasyim Kasim ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Ii ◽  
University Hospital ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Elisa Method ◽  
Cross Sectional ◽  
Stage Renal Disease ◽  
End Stage

This study aimed to analyze endocan levels as a marker of endothelial dysfunction in the control group, patients withstage I hypertension, stage II hypertension, and patients with end-stage renal disease. Endocan levels were measured withESM-1 (endocan) kit by Enzyme-Linked Immunosorbent Assay (ELISA) method. This study used a cross-sectional methodand was conducted in Dr. Wahidin Sudirohusodo Hospital, Makassar and Hasanuddin University Hospital from Septemberto October 2017. There were 83 samples in this study, consisting of 12 samples in the control group, 22 samples of stage Ihypertension, 28 samples of stage II hypertension, and 21 samples of end-stage renal disease aged 20-90 years old. Thisstudy showed significantly higher endocan levels in patients with stage II hypertension and end-stage renal disease(p< 0.05). Endocan levels were significantly higher (p<0.05) in patients with end-stage renal disease compared with thecontrol group and patients with stage I hypertension; but not significantly higher (p > 0.05) compared to patients with stageII hypertension. Also, the median of endocan levels in patients with the end-stage renal disease was higher (309,850 ng/L)compared to patients with stage II hypertension (273,050 ng/L).

Immunodiagnosis and molecular validation of Toxoplasma gondii infection among patients with end-stage renal disease undergoing haemodialysis

Parasitology ◽  
2019 ◽  
Vol 146 (13) ◽  
pp. 1683-1689 ◽  
Author(s):  
Zahra Arab-Mazar ◽  
Shirzad Fallahi ◽  
Davood Yadegarynia ◽  
Amirreza Javadi Mamaghani ◽  
Seyyed Javad Seyyed Tabaei ◽  
...  
Keyword(s):  
Toxoplasma Gondii ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Immunoglobulin M ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Blood Samples ◽  
Igm Antibodies ◽  
Stage Renal Disease ◽  
End Stage

AbstractInfection is a significant cause of morbidity and mortality in patients with chronic kidney disease, especially who were under dialysis due to their depressed immunity. Toxoplasma gondii is a ubiquitous parasite that causes severe manifestations in immunocompromised patients. This case-control study was conducted to the immunodiagnosis and molecular validation of T. gondii infection among patients with end-stage renal disease undergoing haemodialysis. The study population consisted of 260 haemodialysis patients and 259 healthy controls referred to the main dialysis centres of Tehran, Iran during 2016. Anti-T. gondii immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies were assessed using enzyme-linked immunosorbent assay. As well, the T. gondii genomic DNA in whole blood samples of IgM-positive patients and healthy controls was evaluated using GRA6-polymerase chain reaction (PCR) and SAG1-loop-mediated isothermal amplification (LAMP) assays. The anti-T. gondii IgG and IgM antibodies were detected in 175 (67.3%) and 18 (7%) of haemodialysis patients and 122 (47%) and 4 (1.5%) of controls, respectively. Two of the 18 blood samples from IgM-positive patients and none of the IgM-positive control subjects were positive by GRA6-PCR. Whereas, nine and two blood samples of IgM-positive patients and controls were positive for Toxoplasma DNA by a SAG1-LAMP technique respectively. The seropositivity of the Toxoplasma IgM antibody was significantly different between haemodialysis patients and healthy controls which was confirmed by PCR and LAMP. The higher prevalence of T. gondii infection in haemodialysis patients compared with the controls proposes that these patients can be a group at risk for toxoplasmosis and screening for toxoplasmosis before dialysis is necessary for the patients.

Sign in / Sign up

Export Citation Format

Share Document